Visiting from the US? Discover Helixafe, our Cancer Driver Interception program →
What we do
About Bioscience
Professionals
Science & innovation News & media Shop NowTalk to an expert
Italianoالعربية中文

Cancer driver interception

CANCER DRIVER INTERCEPTION

Intercepting cancer development before the advanced disease

Cancer Driver Interception Program

What is the best strategy for fighting cancer? The most ideal situation is undoubtedly one in which it is possible to prevent its development. And prevention is not only a passive process, such as avoiding tobacco smoke to prevent lung cancer. In fact, cancer can be intercepted at any point before the development of advanced disease by a new, active approach – the same as that adopted to fight cardiovascular diseases: monitoring the factors that promote their development and acting on them (as it is done with blood pressure and cholesterol levels). In this way, it is possible both to identify situations of increased risk and to evaluate the effectiveness of treatments aimed at prevention.

The expression “cancer interception” captures the idea of actively intercepting cancer development before the advanced disease presents in the clinic.

The innovative strategy developed by the experts of the Bioscience Institute aims precisely to capture the causes of the increased risk of developing a tumor. In this way, it is possible to really prevent cancer, in contrast to the approaches aimed at early diagnosis. In fact, the latter do not detect an increase in the risk of cancer, but the presence of a tumor mass which, although in the preliminary stages of its development, is already present.

The advantages

By acting on the causes of cancer, it is always possibile to counteract its development.

On the contrary, it is not always possible to act effectively on a tumor that has already developed.
Monitoring the factors that promote the increased risk of cancer (that is, the cancer drivers) allows us to effectively fight the disease already in the 5-15 years preceding its onset.

The strategy

The approach developed by the Bioscience Institute is based on the capture of genomic instability (the leading physiological condition that drives cancer development) and other important cancer drivers that can both promote genomic instability or insist on it, resulting in the amplification of the risk of cancer:

    • chronic inflammation
    • imbalance of the immune defenses
    • imbalance of the bacterial flora

Four tests are proposed:
HELIXBALANCE, CYTOBALANCE, MICROBALANCE, IMMUNEBALANCE.

Each monitors a possible cause of the increased risk of cancer. The results obtained make it possible to develop strategies to keep this risk at bay and, if possible, reduce it.

By regularly repeating the analyses, it is possible to identify cases in which a low risk has increased and to monitor the effectiveness of the strategies adopted to reduce it.

Helixbalance instabilita genomica

HELIXBALANCE- Genomic instability

The analysis of the factors involved in the maintenance of genetic stability makes it possible to act on the prodromal, asymptomatic phase, which precedes the onset of solid.

Learn more

Cytobalance infiammazione cronica

CYTOBALANCE - Chronic inflammation

Chronic low-grade inflammation endangers health without triggering obvious symptoms, favoring the development of chronic diseases, including cancer.

Learn more

Dbalance bilanciamento vitaminico

IMMUNEBALANCE - Immune system

Immunosenescence is one of the mechanisms underlying the link between advancing age and the appearance of diseases involving the immune system, including tumors.

Learn more

Microbalance microbioma intestinale

MICROBALANCE - Intestinal microbiome

The association between microbiota, inflammation and the immune system influences the development of cancer, both locally and systemically.

Learn more

Scientific content reviewed by the Bioscience Institute Scientific Board. · Last updated

The information on this page is for general education and does not replace a consultation with a physician.

This page in other languages: Italiano 中文

Cancer driver interception

Request information

Tell us your situation and a specialist from this area will get back to you, in your country and your language.

HELIXAFE reads biological drivers over time; it is not a diagnostic test and does not replace the screening programmes recommended for your age.

Cancer driver interception

Periodic monitoring of the four biological drivers that precede cancer, through five laboratory protocols.

Periodic monitoring of the four biological drivers that precede cancer: genomic instability, microbiome dysbiosis, chronic inflammation and immune dysfunction. A patented method, published in Cell Death & Disease.

Connect with us on social

Helixafe · US